Anti-CCL2 [CNTO 888 (Carlumab)]
Catalogue Number: AB02245-3.0-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | MCP-1; MCP1; HC11; MCAF; C-C motif chemokine 2; monocyte chemoattractant protein 1; monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; Small-inducible cytokine A2 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Mouse |
| Clone: | CNTO 888 (Carlumab) |
| Isotype: | IgG2b |
| Immunogen: | The original antibody was generated by phage display using the Human Combinatorial Antibody Library (HuCAL GOLD). |
| Application: | Blk, Inh |
Additional Text
Uniprot ID
P13500
Gene Name
CCL2
Gene ID
6347
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Application Notes
CCL2 is implicated in the pathogenesis of certain inflammatory diseases and cancer. Binding of CCL2 to its receptor CCR2 triggers calcium mobilization and chemotaxis. CNTO 888 is a neutralizing anti-CCL2 antibody that binds human CCL2 with high affinity of Kd=22pM and inhibits CCL2 binding to its receptor. The systemic administration of anti-CCL2 neutralizing antibodies (CNTO888 and C1142) significantly retarded tumor growth and attenuated CD68+ macrophage infiltration, which was accompanied by a significant decrease in microvascular density (PMID: 17710158). Phase 1 trials in 44 patients with solid tumors concluded that CNTO888 was well tolerated in individuals with evidence of transient free CCL2 suppression and preliminary antitumor activity (PMID: 23385782). This antibody was also capable of inhibiting growth of breast cancer when administered individually or as a cocktail (Campion et al, 2009). A phase 2 study in 46 patients with castration-resistant prostate cancer (CRPC) concluded that carlumab was well-tolerated but did not block the CCL2/CCR2 axis or show antitumor activity as a single agent in metastatic CRPC (PMID: 22907596).
Short Description
This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
AB02245-3.0-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations